MD3522880T2 - Metode de tratare a leziunilor renale acute - Google Patents

Metode de tratare a leziunilor renale acute

Info

Publication number
MD3522880T2
MD3522880T2 MDE20190903T MDE20190903T MD3522880T2 MD 3522880 T2 MD3522880 T2 MD 3522880T2 MD E20190903 T MDE20190903 T MD E20190903T MD E20190903 T MDE20190903 T MD E20190903T MD 3522880 T2 MD3522880 T2 MD 3522880T2
Authority
MD
Moldova
Prior art keywords
methods
kidney injury
acute kidney
treating acute
treating
Prior art date
Application number
MDE20190903T
Other languages
English (en)
Inventor
Bharat Lagu
Michael Patane
Effie Tozzo
Scott Trzaska
Original Assignee
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitobridge Inc filed Critical Mitobridge Inc
Publication of MD3522880T2 publication Critical patent/MD3522880T2/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Prezenta invenţie se referă la metode de tratare a unui pacient uman cu leziuni renale acute.
MDE20190903T 2016-10-05 2017-10-05 Metode de tratare a leziunilor renale acute MD3522880T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404390P 2016-10-05 2016-10-05
PCT/US2017/055400 WO2018067857A1 (en) 2016-10-05 2017-10-05 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
MD3522880T2 true MD3522880T2 (ro) 2021-03-31

Family

ID=60153507

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20190903T MD3522880T2 (ro) 2016-10-05 2017-10-05 Metode de tratare a leziunilor renale acute

Country Status (32)

Country Link
US (1) US20210283116A1 (ro)
EP (1) EP3522880B1 (ro)
JP (1) JP7065839B2 (ro)
KR (1) KR20190062502A (ro)
CN (1) CN109789117B (ro)
AU (1) AU2017340760B2 (ro)
BR (1) BR112019005539A2 (ro)
CA (1) CA3036723A1 (ro)
CO (1) CO2019004561A2 (ro)
CY (1) CY1124759T1 (ro)
DK (1) DK3522880T3 (ro)
ES (1) ES2859487T3 (ro)
HR (1) HRP20210294T1 (ro)
HU (1) HUE053557T2 (ro)
IL (1) IL265749A (ro)
JO (1) JOP20190056B1 (ro)
LT (1) LT3522880T (ro)
MA (1) MA46459B1 (ro)
MD (1) MD3522880T2 (ro)
MX (1) MX2019003949A (ro)
MY (1) MY192385A (ro)
PH (1) PH12019500725A1 (ro)
PL (1) PL3522880T3 (ro)
PT (1) PT3522880T (ro)
RS (1) RS61573B1 (ro)
RU (1) RU2753607C2 (ro)
SG (1) SG11201901925RA (ro)
SI (1) SI3522880T1 (ro)
TW (1) TWI778982B (ro)
UA (1) UA124019C2 (ro)
WO (1) WO2018067857A1 (ro)
ZA (1) ZA201901743B (ro)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3795566B1 (en) 2015-10-07 2023-04-19 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
US11358954B2 (en) * 2016-04-13 2022-06-14 Mitobridge, Inc. PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
CN109843857B (zh) 2016-10-05 2023-01-06 米托布里奇公司 Ppar激动剂化合物的结晶和盐形式
JP2022541783A (ja) 2019-07-19 2022-09-27 ヴィフォール (インターナショナル) アクチェンゲゼルシャフト 腎臓損傷の予防及び治療で使用するためのフェロポーチン阻害剤
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1670744T3 (pl) * 2003-09-19 2011-01-31 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i ich analogi
US7323480B2 (en) * 2004-05-25 2008-01-29 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
RU2320341C1 (ru) * 2006-06-13 2008-03-27 Государственное учреждение Научный центр реконструктивной и восстановительной хирургии Восточно-Сибирского научного центра Сибирского отделения Российской Академии медицинских наук Средство для лечения острой обструкции верхних мочевыводящих путей
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
WO2010045361A1 (en) * 2008-10-17 2010-04-22 Metabolex, Inc. Methods of reducing small, dense ldl particles
US7928067B2 (en) * 2009-05-14 2011-04-19 Ischemix Llc Compositions and methods for treating ischemia and ischemia-reperfusion injury
EP2964671A4 (en) * 2013-03-08 2016-08-31 Abbvie Inc METHODS OF TREATING ACUTE RENAL FAILURE
EP2981522A4 (en) * 2013-04-05 2016-08-31 Salk Inst For Biological Studi ANTAGONISTS OF PPAR
EP2862574A1 (en) * 2013-10-15 2015-04-22 Sanofi {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
EP3077819A4 (en) * 2013-12-03 2017-06-28 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20170305894A1 (en) * 2014-10-08 2017-10-26 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016057656A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar-delta agonists for use for treating mitochondrial, vascular, muscular, and demyelinating diseases
EP3795566B1 (en) * 2015-10-07 2023-04-19 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof

Also Published As

Publication number Publication date
SG11201901925RA (en) 2019-04-29
JP2019533660A (ja) 2019-11-21
SI3522880T1 (sl) 2021-07-30
BR112019005539A2 (pt) 2019-06-18
MX2019003949A (es) 2019-06-10
IL265749A (en) 2019-06-30
UA124019C2 (uk) 2021-07-07
PT3522880T (pt) 2021-02-22
PL3522880T3 (pl) 2021-08-23
JP7065839B2 (ja) 2022-05-12
MY192385A (en) 2022-08-18
LT3522880T (lt) 2021-03-25
ZA201901743B (en) 2022-04-28
TWI778982B (zh) 2022-10-01
EP3522880B1 (en) 2020-12-02
CA3036723A1 (en) 2018-04-12
WO2018067857A1 (en) 2018-04-12
HUE053557T2 (hu) 2021-07-28
JOP20190056B1 (ar) 2022-03-14
RU2019111421A3 (ro) 2021-02-05
RS61573B1 (sr) 2021-04-29
RU2019111421A (ru) 2020-11-06
RU2753607C2 (ru) 2021-08-18
JOP20190056A1 (ar) 2019-03-24
CO2019004561A2 (es) 2019-07-31
MA46459A (fr) 2019-08-14
DK3522880T3 (en) 2021-01-18
KR20190062502A (ko) 2019-06-05
PH12019500725A1 (en) 2019-08-05
EP3522880A1 (en) 2019-08-14
CN109789117B (zh) 2022-08-23
AU2017340760B2 (en) 2023-07-27
AU2017340760A1 (en) 2019-03-21
CY1124759T1 (el) 2022-07-22
TW201815391A (zh) 2018-05-01
MA46459B1 (fr) 2021-03-31
HRP20210294T1 (hr) 2021-04-16
US20210283116A1 (en) 2021-09-16
CN109789117A (zh) 2019-05-21
ES2859487T3 (es) 2021-10-04

Similar Documents

Publication Publication Date Title
MD3522880T2 (ro) Metode de tratare a leziunilor renale acute
DK3668562T3 (da) Blodpumpe
DK3386511T3 (da) Fremgangsmåder til behandling af huntingtons sygdom
DK3912673T3 (da) Blodpumpe
DK3413948T3 (da) Blodpumpesystem
DK3359214T3 (da) Blodpumpe
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201890441A1 (ru) Моноклональные антитела против bcma
DK3069739T3 (da) Blodpumpe
DK3474841T3 (da) Fremgangsmåder til behandling af ar+-brystkræft
DK3069740T3 (da) Blodpumpe
DK3069738T3 (da) Blodpumpe
DK3357523T3 (da) Blodpumpe
CL2017002781A1 (es) Métodos de tratamiento de enfermedad de alzheimer
DK3684439T3 (da) Blodpumpe
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MA46284A (fr) Canule cardiaque
EA201692534A1 (ru) Способы лечения гипотонии
DE112017004905A5 (de) Blutpumpe
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
ES2894844T8 (es) Tratamiento de la calcificación vascular
DK3580182T3 (da) Vandbehandling
FR3058067B1 (fr) Systeme d'assistance circulatoire
BR112018006053A2 (pt) máquina de diálise.
BR112017028608A2 (pt) músculo cardíaco humanizado